For eligible adults with clinically significant obesity, MHRA-approved options include semaglutide (Wegovy, assessed in NICE TA875) and tirzepatide (Mounjaro, assessed in NICE TA1026), both available through NHS pathways with appropriate clinical oversight
Beyond their role in addiction, GLP-1 receptor agonists are used in a range of medical conditions, including type 2 diabetes, obesity, cardiovascular disease, liver and kidney health, and emerging research in neurodegenerative disorders
For more information about semaglutide, please contact Dermacare Medical Aesthetics at 858-487-3376
(2008) seven patients with CPTII deficiency were subjected to a dietary regimen including carbohydrates reduction (37%) in favor to triheptanoin and no episodes of rhabdomyolysis or major muscle complaints were experienced, despite an overall increase in daily physical activity